SCHEMBL677488

SCHEMBL677488

CC(C)(C)COc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.50
LTA4H P09960 2/20 0.46
HTR1B P28222 2/20 0.45
LMNA P02545 1/20 0.45
HTR1D P28221 1/20 0.45
TAAR1 Q96RJ0 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RECQL P46063 1/20 0.44
RIPK1 Q13546 1/20 0.44
CYP2D6 P10635 1/20 0.43
ALOX15 P16050 1/20 0.43
PDK2 Q15119 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA7 P36544 1/20 0.42
CHRNA4 P43681 1/20 0.42
KCNH2 Q12809 1/20 0.42
CA4 P22748 1/20 0.42
GABRP O00591 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13141341 0.87 NQO1 (0.48) LTA4HALDH1A1PDK2GABRPGABRD
SCHEMBL7462021 0.87 NPC1 (0.51) LTA4HLMNAALDH1A1CHRNB2CHRNB4
SCHEMBL4984322 0.85 KCNA3 (0.50) KCNA3LTA4HHTR1BLMNAHTR1D
SCHEMBL2200517 0.85 KCNA3 (0.50) KCNA3LTA4HHTR1BLMNAHTR1D
SCHEMBL10645031 0.84 ALOX15 (0.41) KCNA3LMNAALDH1A1RECQLCYP2D6
SCHEMBL12250936 0.83 LMNA (0.60) LMNA
SCHEMBL10534532 0.83 PDK2 (0.45) LMNAALDH1A1PDK2CHRNB2CHRNA4
SCHEMBL10713342 0.82 KCNA3 (0.43) KCNA3LTA4HHTR1BLMNAHTR1D
SCHEMBL12250931 0.82 GGPS1 (0.56) LTA4HPDK2
SCHEMBL25053084 0.81 KCNA3 (0.46) KCNA3LTA4HHTR1BLMNAHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4277591-A1 ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR Momentive Performance Materials GmbH (DE) 2023-11-22 EP claimed
CN-116670108-A Ether compounds as volatiles for treating amino acid based substrates such as skin and hair 迈图高新材料有限责任公司 2023-08-29 CN claimed
WO-2022152742-A1 ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) 2022-07-21 WO claimed
EP-3203541-B1 ORGANIC SEMICONDUCTOR COMPOSITION FUJIFILM CORP (JP) 2022-07-06 EP claimed
EP-3203541-A1 ORGANIC SEMICONDUCTOR COMPOSITION AND ORGANIC SEMICONDUCTOR ELEMENT Fujifilm Corporation (JP) 2017-08-09 EP claimed
US-20170125694-A1 ORGANIC SEMICONDUCTOR COMPOSITION AND ORGANIC SEMICONDUCTOR ELEMENT FUJIFILM CORPORATION (JP) 2017-05-04 US claimed
EP-2266949-B1 \"Fast, high-efficiency quantitative synthesis of paracetamol\ GREGORIO LIBERATA (IT) 2013-05-29 EP claimed
EP-2266949-A1 \"Fast, high-efficiency quantitative synthesis of paracetamol\ Gregoria, Liberata (IT) 2010-12-29 EP claimed
US-12350296-B2 Liquid propolis extract, its formulation and use thereof ApiotiX Technologies d.o.o. (HR) 2025-07-08 US disclosed
WO-2024078851-A1 CATALYTIC COMPOSITIONS Universität Heidelberg (DE) 2024-04-18 WO disclosed
US-20240018298-A1 OLEFINIC COMPOSITIONS COMPRISING HYDROCARBON RESINS ExxonMobil Product Solutions Company 2024-01-18 US disclosed
US-20240018298-A1 OLEFINIC COMPOSITIONS COMPRISING HYDROCARBON RESINS ExxonMobil Product Solutions Company 2024-01-18 US disclosed
US-20230372292-A1 TREATMENTS OF CORONAVIRUS INFECTIONS, CYTOKINE RELEASE SYNDROME, CYTOKINE STORM SYNDROME, OR DISEASES ASSOCIATED WITH EXCESSIVE ACTIVATION OF INFLAMMASOMES BY THE USE OF INHIBITORS OF INFLAMMATORY CASPASES IPCURE S.A.S. (FR) 2023-11-23 US disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
EP-0977743-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-02-09 EP disclosed
WO-1998049152-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed
US-4837301-A FROM ALKALI MTEAL SULFIDES AND AROMATIC DIHALOGEN COMPOUNDS; IMPROVED CORROSION RESISTANCE BAYER AKTIENGESELLSCHAFT (DE) 1989-06-06 US disclosed
EP-0275007-A2 Process for the preparation of highly molecular, optionally branched polyarylene sulfides BAYER AG (DE) 1988-07-20 EP disclosed
EP-0273242-A2 2-Pyri(mi)dylthio-aryl ether BAYER AG (DE) 1988-07-06 EP disclosed
US-4066707-A METHOD FOR MANUFACTURE OF DIPHENOLS AND MONOALKYL ETHERS OF DIPHENOLS AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JA) 1978-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786575-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 KCNA3 3161/4885LTA4H 256/4885HTR1B 2340/4885
US-12350296-B2 Liquid propolis extract, its formulation and use thereof CUTA, LITAF, ALB KCNA3 4511/4885LTA4H 764/4885HTR1B 4881/4885
US-20230372292-A1 TREATMENTS OF CORONAVIRUS INFECTIONS, CYTOKINE RELEASE SYNDROME, CYTOKINE STORM SYNDROME, OR DISEASES ASSOCIATED WITH EXCESSIVE ACTIVATION OF INFLAMMASOMES BY THE USE OF INHIBITORS OF INFLAMMATORY CASPASES CASP1, IL1B, PYCARD KCNA3 1904/4885LTA4H 414/4885HTR1B 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.